However, the effect was diminished for luminal B [HER2-negative] (HR: 6.43 [2.62–15.80]), basal (HR: 5.46 [2.05–14.54]) and luminal A (HR: 2.85 [1.31–6.18]), and was not significant for luminal B [HER2-positive] and HER2-enriched, upon adjusting for other treatments, tumor characteristics and patient’s demographics. The gene discussed is ERBB2; the disease is neoplasm.